- Poster presentation
- Open Access
Expansion of mesenchymal adipose-tissue derived stem cells in a stirred single-use bioreactor under low-serum conditions
© Schirmaier et al.; licensee BioMed Central Ltd. 2013
- Published: 4 December 2013
- Computational Fluid Dynamic
- Expansion Rate
- Computational Fluid Dynamic Simulation
- Human Mesenchymal Stem Cell
- Culture Volume
The need for human mesenchymal stem cells (hMSCs) has increased enormously in recent years due to their important therapeutic potential. Efficient cell expansion is essential to providing clinically relevant cell numbers. Such cell quantities can be manufactured by means of scalable microcarrier (MC)-supported cultivations in stirred single-use bioreactors.
Preliminary tests in disposable-spinners (100 mL culture volume, Corning) were used to determine two suitable media and MC-types for serum reduced expansions (< 10%) of human adipose tissue-derived stem cells (hADSCs; passage 2, Lonza). Using such optimized media-MC-combinations, hADSCs expanded 30 to 40-fold, which compares well with expansion rates in planar culture. Based on computational fluid dynamics simulations and suspension analyses in spinners , optimal operating parameters were determined in a BIOSTAT® UniVessel® SU 2 L (2 L culture volume, Sartorius Stedim Biotech).
In subsequent batch tests with the BIOSTAT UniVessel® SU 2 L, expansion rates of between 30 and 40-fold were reached and up to 4.4·108 cells with a cell viability exceeding 98% were harvested. Flow cytometry tests demonstrated typical marker profiles following cell expansion and harvest. A 40-fold expansion rate delivered a total of 1·1010 cells in a first cultivation with the BIOSTAT® CultiBag STR 50 L (35 L culture volume, Sartorius Stedim Biotech).
In summary, the foundations for successfully expanding therapeutic stem cells in truly scalable systems have been laid. Strategies ensuring expansion rates between 60 and 70-fold and, thus, generating cell amounts over 1010 are now in preparation.
This work is part of the project "Development of a technology platform for a scalable production of therapeutically relevant stem cells" (No. 12893.1 VOUCH-LS). It is supported by the Commission for Technology and Innovation (CTI, Switzerland). The authors would like to thank the CTI for partially financing the investigations presented.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.